标题
mTOR Signaling Pathway in Cancer Targets Photodynamic Therapy In Vitro
作者
关键词
-
出版物
Cells
Volume 8, Issue 5, Pages 431
出版商
MDPI AG
发表日期
2019-05-13
DOI
10.3390/cells8050431
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Targeting Phosphatidylinositol 3-Kinase Signaling Pathway for Therapeutic Enhancement of Vascular-Targeted Photodynamic Therapy
- (2017) Daniel Kraus et al. MOLECULAR CANCER THERAPEUTICS
- Type I and Type II Photosensitized Oxidation Reactions: Guidelines and Mechanistic Pathways
- (2017) Maurício S. Baptista et al. PHOTOCHEMISTRY AND PHOTOBIOLOGY
- ALA-PDT suppressing the cell growth and reducing the lipogenesis in human SZ95 sebocytes by mTOR signaling pathway in vitro
- (2017) Jiang Tuo et al. Photodiagnosis and Photodynamic Therapy
- Oncologic Photodynamic Therapy: Basic Principles, Current Clinical Status and Future Directions
- (2017) Demian van Straten et al. Cancers
- Phase II study of oral ridaforolimus in patients with metastatic and/or locally advanced recurrent endometrial cancer: NCIC CTG IND 192.
- (2017) H. Mackay et al. JOURNAL OF CLINICAL ONCOLOGY
- Current Treatment of Metastatic Endometrial Cancer
- (2017) Sarah M. Temkin et al. Cancer Control
- New photosensitizers for photodynamic therapy
- (2016) H. Abrahamse et al. BIOCHEMICAL JOURNAL
- New perspectives on mTOR inhibitors (rapamycin, rapalogs and TORKinibs) in transplantation
- (2016) Matthias Waldner et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer
- (2016) David R. Driscoll et al. CANCER RESEARCH
- The Mechanistic Target of Rapamycin: The Grand ConducTOR of Metabolism and Aging
- (2016) Brian K. Kennedy et al. Cell Metabolism
- Structural insights of mTOR complex 1
- (2016) Hai-Xin Yuan et al. CELL RESEARCH
- Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study
- (2016) James C Yao et al. LANCET
- Metabolic maintenance of cell asymmetry following division in activated T lymphocytes
- (2016) Katherine C. Verbist et al. NATURE
- Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
- (2016) Vanessa S. Rodrik-Outmezguine et al. NATURE
- mTORC1 and mTORC2 in cancer and the tumor microenvironment
- (2016) L C Kim et al. ONCOGENE
- Management of side effects of mTOR inhibitors in tuberous sclerosis patients
- (2016) Krzysztof Sadowski et al. Pharmacological Reports
- mTOR inhibitors in urinary bladder cancer
- (2016) R. Pinto-Leite et al. TUMOR BIOLOGY
- Is mTOR Inhibitor Good Enough for Treatment All Tumors in TSC Patients?
- (2016) Samy L Habib et al. Journal of Cancer
- Comparison between endothelial and tumor cells in the response to verteporfin-photodynamic therapy and a PI3K pathway inhibitor
- (2015) Babasola Fateye et al. Photodiagnosis and Photodynamic Therapy
- Architecture of human mTOR complex 1
- (2015) C. H. S. Aylett et al. SCIENCE
- Current treatment strategies for inhibiting mTOR in cancer
- (2015) Francesca Chiarini et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades
- (2015) James Andrew McCubrey et al. Oncotarget
- Computer-Aided Targeting of the PI3K/Akt/mTOR Pathway: Toxicity Reduction and Therapeutic Opportunities
- (2014) Tan Li et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial
- (2014) Fabrice André et al. LANCET ONCOLOGY
- Making new contacts: the mTOR network in metabolism and signalling crosstalk
- (2014) Mitsugu Shimobayashi et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Deciphering Combinations of PI3K/AKT/mTOR Pathway Drugs Augmenting Anti-Angiogenic Efficacy In Vivo
- (2014) Temitope Sasore et al. PLoS One
- Photodynamic Therapy and Its Role in Combined Modality Anticancer Treatment
- (2014) N. Patrik Brodin et al. TECHNOLOGY IN CANCER RESEARCH & TREATMENT
- A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity
- (2014) B. C. Grabiner et al. Cancer Discovery
- Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib
- (2014) N. Wagle et al. Cancer Discovery
- A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy
- (2013) Sara A. Hurvitz et al. BREAST CANCER RESEARCH AND TREATMENT
- Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial
- (2013) Howard A. Burris et al. CANCER
- Targeting the mTOR Pathway in Tumor Malignancy
- (2013) Hengmiao Cheng et al. CURRENT CANCER DRUG TARGETS
- Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199)
- (2013) A.V. Tinker et al. GYNECOLOGIC ONCOLOGY
- Mutational landscape and significance across 12 major cancer types
- (2013) Cyriac Kandoth et al. NATURE
- Development of PI3K inhibitors: lessons learned from early clinical trials
- (2013) Jordi Rodon et al. Nature Reviews Clinical Oncology
- Synergistic effect of radachlorin mediated photodynamic therapy on propolis induced apoptosis in AMC-HN-4 cell lines via caspase dependent pathway
- (2013) Jin-Chul Ahn et al. Photodiagnosis and Photodynamic Therapy
- The Paradox of Akt-mTOR Interactions
- (2013) Lakshmipathi Vadlakonda et al. Frontiers in Oncology
- Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells
- (2012) Benjamin Blaser et al. BMC CANCER
- mTOR inhibitors in cancer therapy
- (2012) Yekaterina Y. Zaytseva et al. CANCER LETTERS
- mTOR Signaling in Growth Control and Disease
- (2012) Mathieu Laplante et al. CELL
- mTOR Signaling in Cancer Cell Motility and Tumor Metastasis
- (2012) Hongyu Zhou et al. CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION
- Targeting the PI3K signaling pathway in cancer therapy
- (2012) Chandra Bartholomeusz et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- mTOR Signaling Pathway and mTOR Inhibitors in Cancer Therapy
- (2012) Alejandro Gomez-Pinillos et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- The mTOR Signalling Pathway in Human Cancer
- (2012) Helena Pópulo et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Transferrin-conjugated polyphosphoester hybrid micelle loading paclitaxel for brain-targeting delivery: Synthesis, preparation and in vivo evaluation
- (2012) Pengcheng Zhang et al. JOURNAL OF CONTROLLED RELEASE
- Combination of Phosphatidylinositol 3-Kinases Pathway Inhibitor and Photodynamic Therapy in Endothelial and Tumor Cells
- (2012) Babasola Fateye et al. PHOTOCHEMISTRY AND PHOTOBIOLOGY
- PI3K and mTOR Signaling Pathways in Cancer: New Data on Targeted Therapies
- (2012) Lise Willems et al. Current Oncology Reports
- Circumventing Cancer Drug Resistance in the Era of Personalized Medicine
- (2012) Levi A. Garraway et al. Cancer Discovery
- Photodynamic therapy of cancer: An update
- (2011) Patrizia Agostinis et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Innovations therapy: mammalian target of rapamycin (mTOR) inhibitors for the treatment of neuroendocrine tumors
- (2011) Jaume Capdevila et al. CANCER AND METASTASIS REVIEWS
- mTORC1 and mTORC2 Regulate EMT, Motility, and Metastasis of Colorectal Cancer via RhoA and Rac1 Signaling Pathways
- (2011) P. Gulhati et al. CANCER RESEARCH
- Decreased Lymphangiogenesis and Lymph Node Metastasis by mTOR Inhibition in Head and Neck Cancer
- (2011) V. Patel et al. CANCER RESEARCH
- mTOR complex 2 signaling and functions
- (2011) Won Jun Oh et al. CELL CYCLE
- An emerging role for TOR signaling in mammalian tissue and stem cell physiology
- (2011) Ryan C. Russell et al. DEVELOPMENT
- Targeting the mTOR kinase domain: the second generation of mTOR inhibitors
- (2011) Yan-Jie Zhang et al. DRUG DISCOVERY TODAY
- RNA interference targeting raptor inhibits proliferation of gastric cancer cells
- (2011) William Ka Kei Wu et al. EXPERIMENTAL CELL RESEARCH
- Activating mutations of TOR (target of rapamycin)
- (2011) Molly Hardt et al. GENES TO CELLS
- Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: A Gynecologic Oncology Group study
- (2011) Kian Behbakht et al. GYNECOLOGIC ONCOLOGY
- Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy
- (2011) Seth A. Wander et al. JOURNAL OF CLINICAL INVESTIGATION
- Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
- (2011) Marianne E Pavel et al. LANCET
- The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2
- (2011) Greg M Delgoffe et al. NATURE IMMUNOLOGY
- Rapamycin passes the torch: a new generation of mTOR inhibitors
- (2011) Don Benjamin et al. NATURE REVIEWS DRUG DISCOVERY
- Everolimus for Advanced Pancreatic Neuroendocrine Tumors
- (2011) James C. Yao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Regulation of mTORC1 Signaling by pH
- (2011) Aruna D. Balgi et al. PLoS One
- Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth
- (2011) Q. Sun et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Clinical activity of mammalian target of rapamycin inhibitors in solid tumors
- (2011) Yesid Alvarado et al. Targeted Oncology
- Oncogenic EGFR Signaling Activates an mTORC2-NF- B Pathway That Promotes Chemotherapy Resistance
- (2011) K. Tanaka et al. Cancer Discovery
- Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
- (2010) T.-C. Chou CANCER RESEARCH
- The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma
- (2010) D. C. Cho et al. CLINICAL CANCER RESEARCH
- Rapamycin Inhibits Cytoskeleton Reorganization and Cell Motility by Suppressing RhoA Expression and Activity
- (2010) Lei Liu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo
- (2010) Didier Roulin et al. Molecular Cancer
- mTOR: from growth signal integration to cancer, diabetes and ageing
- (2010) Roberto Zoncu et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Rapamycin inhibits mTORC1, but not completely
- (2009) Carson C. Thoreen et al. Autophagy
- Dual chemotherapy and photodynamic therapy in an HT-29 human colon cancer xenograft model using SN-38-loaded chlorin-core star block copolymer micelles
- (2009) Cheng-Liang Peng et al. BIOMATERIALS
- mTOR Complex 2 Is Required for the Development of Prostate Cancer Induced by Pten Loss in Mice
- (2009) David A. Guertin et al. CANCER CELL
- mTOR Is a Promising Therapeutic Target Both in Cisplatin-Sensitive and Cisplatin-Resistant Clear Cell Carcinoma of the Ovary
- (2009) S. Mabuchi et al. CLINICAL CANCER RESEARCH
- Targeted Inhibition of Mammalian Target of Rapamycin Signaling Inhibits Tumorigenesis of Colorectal Cancer
- (2009) P. Gulhati et al. CLINICAL CANCER RESEARCH
- Rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosis
- (2009) Aaron Shafer et al. INTERNATIONAL JOURNAL OF CANCER
- Targeted inhibition of the EGFR pathways enhances Zn-BC-AM PDT-induced apoptosis in well-differentiated nasopharyngeal carcinoma cells
- (2009) Ho-Kee Koon et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Targeting the mTOR Signaling Network for Cancer Therapy
- (2009) Funda Meric-Bernstam et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
- (2009) Georg Hess et al. JOURNAL OF CLINICAL ONCOLOGY
- The Pharmacology of mTOR Inhibition
- (2009) D. A. Guertin et al. Science Signaling
- Oncogene Addiction
- (2008) I. B. Weinstein et al. CANCER RESEARCH
- Mediobasal Hypothalamic p70 S6 Kinase 1 Modulates the Control of Energy Homeostasis
- (2008) Clémence Blouet et al. Cell Metabolism
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
- Photodynamic Therapy Targets the mTOR Signaling Networkin Vitroandin Vivo
- (2008) Anette Weyergang et al. MOLECULAR PHARMACEUTICS
- PI3K pathway alterations in cancer: variations on a theme
- (2008) T L Yuan et al. ONCOGENE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started